AllerGenis LLC today announced that positive new data about an innovative approach to track the progress of peanut allergy desensitization utilizing AllerGenis' Epitope Mapping Platform in children undergoing epicutaneous immunotherapy for peanut allergy (DBV712 250 µg) being developed by DBV Technologies, will be presented at the American College of Allergy and Asthma & Immunology (ACAAI) virtual 2020 Annual Scientific Meeting. The presentation, a partnership with DBV Technologies, is titled, "Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy," and will be given by David Fleischer, MD, Professor of Pediatrics and Section Head, Children's Hospital Colorado, at 3:33 p.m. CST on Saturday, November 14. Access full abstract here.

The results to be presented at ACAAI are based on samples from subjects who participated in the Efficacy and Safety of Viaskin Peanut in Children with Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES) study (NCT02636699). This was a Phase 3, double-blind, randomized controlled trial of children aged four to 11 years with peanut allergies who were treated with DBV712 250 µg or placebo for 12 months. Daily treatment with investigational DBV712 250 µg (approximately 1/1000 one peanut) was shown to result in a statistically significant increase in desensitization in peanut-allergic children aged four to 11 years compared with placebo.

read press release →

AllerGenis LLC today announced the onset of operations at its Hatfield facility to test patient samples using its VeriMAPTM Peanut Diagnostic, a diagnostic solution for patients with peanut allergies. AllerGenis received full certification under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform its high complexity clinical laboratory testing. This is a crucial step for the company as it begins offering VeriMAP Peanut Diagnostic to Centers of Excellence and community allergists over the next few months, with plans to expand into additional allergy centers in early 2021.

"It has been decades since the last technological breakthrough in food allergy diagnosis," says Jim Garner, CEO of AllerGenis.

read press release →

Company to present validation data of its VeriMAPTM Peanut Diagnostic and showcase the broad application of its next-generation food allergy diagnostic platform to assess response to immunotherapy

Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th through 8th. AllerGenis will have two presentations at the Congress, which are include:

• Thematic Poster Presentation: Repeated validation of a high-performing peanut allergy diagnostic on POISED trial subjects
  Presenter: Paul Kearney, Head of Product and Clinical Development, AllerGenis; and

• Late Breaking Oral Abstract Presentation: Differences in epitome response in peanut-allergic subjects treated with different immunotherapy preparations
  Presenter: Dianne Campbell, VP, Scientific and Medical Affairs, Australia and New Zealand, DBV Technologies

Both presentations will be available to conference registrants from EAACI’s website up to six months after the event.

read press release →

AllerGenis today announced that CEO Jim Garner will be presenting during the Biotech Showcase at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Mr. Garner’s presentation will highlight the upcoming 2020 introduction of AllerGenis’ food allergy diagnostic platform, which more than triples diagnostic precision compared to current food allergy testing.

The presentation, titled, “Revolutionizing the Diagnosis and Management of Food Allergy,” can be webcast live (Link), and will be available for streaming on the “Resources” section of the company’s website, www.allergenis.com, following the presentation.

read press release →

Newly published peer-reviewed paper in Scientific Reports from Nature demonstrates concordance between epitope mapping and oral food challenge for diagnosing peanut and milk allergies

AllerGenis this week reported research results in Scientific Reports from Nature, in preparation for the clinical launch of its bead-based epitope mapping diagnostic platform. The study quantified and validated the performance of the platform against the widely used peptide microarray assays in clinical patient populations.

“There still remains a significant unmet for improved food allergy diagnostics,” said Bob Getts, PhD., Chief Science Officer at AllerGenis and co-author of the study. “These results demonstrate that AllerGenis’ platform not only is orders of magnitude more powerful based on throughput than conventional epitope analysis methods, but also is more sensitive and reliable than current food allergy tests and can be conducted at clinical scale. We’re excited about the potential of empowering patients to find clarity about their food allergies through our platform.”

read press release →

Sensitivity of food allergy diagnosis, assessment, and monitoring will more than triple using precision, multiplexed immunoassay technology

AllerGenis, LLC today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX). According to the terms, AllerGenis will have the rights to develop, market and sell its novel precision food allergy diagnostic assay using Luminex’s xMAP® Technology.

The agreement supports the upcoming 2019 commercialization of AllerGenis’ food allergy diagnostic platform, which more than triples diagnostic precision compared to current food allergy tests.

“We have been able to scientifically demonstrate the ability to identify food allergies with much higher precision over currently available blood tests. We’re very excited to enter into this agreement with Luminex to bring this much-needed technology to the clinical setting as soon as possible.”

read press release →